H Tilly
Impact in
- Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research
Papers in
- Genetics 14
- Chronic Lymphocytic Leukemia Research 13
- Hematology 13
- Acute Myeloid Leukemia Research 8
- Hematopoietic Stem Cell Transplantation 4
H Tilly
43 papers receiving 1.9k citations
Hit Papers
Peers
Comparison fields: 5 of 73
- Pathology and Forensic Medicine 1.3k
- Genetics 674
- Hematology 460
- Oncology 856
- Neurology 350
Countries citing papers authored by H Tilly
This map shows the geographic impact of H Tilly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H Tilly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H Tilly more than expected).
Fields of papers citing papers by H Tilly
This network shows the impact of papers produced by H Tilly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H Tilly. The network helps show where H Tilly may publish in the future.
Co-authorship network
The 25 scholars most cited alongside H Tilly, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | びまん性大細胞型B細胞非Hodgkinリンパ腫 診断,治療および追跡のためのESMO診療ガイドライン | 2010 | 8 |
| 2 | 2010 | 5 | |
| 3 | 2006 | 7 | |
| 4 | [Acute respiratory distress syndrome due to pneumonitis following intrathecal methotrexate administration]. | 2003 | 3 |
| 5 | Final results of the efficacy and safety of rasburicase (recombinant urate oxydase) for the prevention and treatment of hyperuricemia in patients with aggressive lymphoma (GRAAL 1 study). | 2002 | 4 |
| 6 | 2002 | 56 | |
| 7 | 2000 | 54 | |
| 8 | 1999 | 11 | |
| 9 | Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Hit paper breakdown → | 1998 | 724 |
| 10 | 1997 | 50 | |
| 11 | 1997 | 162 | |
| 12 | 1996 | 127 | |
| 13 | 1994 | 24 | |
| 14 | 1993 | 126 | |
| 15 | 1992 | 79 | |
| 16 | [Production of hyaluronan-binding glycoprotein by human monocytes. Its use as marker in myeloid leukemia]. | 1992 | 2 |
| 17 | 1991 | 44 | |
| 18 | 1989 | 213 | |
| 19 | 1987 | 4 | |
| 20 | Hépatite chronique compliquée de cirrhose, due à la papavérine. | 1981 | 3 |
About H Tilly
H Tilly is a scholar working on Genetics, Hematology, Pathology and Forensic Medicine, Transplantation and Dermatology, having authored 44 papers that have together received 2.0k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (20 papers), Chronic Lymphocytic Leukemia Research (13 papers), Acute Myeloid Leukemia Research (8 papers), Acute Lymphoblastic Leukemia research (7 papers), Viral-associated cancers and disorders (4 papers), Hematopoietic Stem Cell Transplantation (4 papers), Retinoids in leukemia and cellular processes (3 papers) and Glycosylation and Glycoproteins Research (2 papers). The work is most often cited by research in Pathology and Forensic Medicine (1.3k citations), Genetics (674 citations), Hematology (460 citations), Oncology (856 citations) and Neurology (350 citations). H Tilly has collaborated with scholars based in France, Belgium and Czechia. Frequent co-authors include Corinne Haïoun, F Reyes, Renaud Capdeville, Volker Diehl, Andreas Engert, Nicolas Ketterer, John Radford, Dengyan Ma, Michaela Feuring Buske and Peter Johnson. Their work appears in journals such as Journal of Clinical Oncology, Blood, Leukemia, Annals of Oncology and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.